RYTM
Rhythm Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$6.02B
P/E Ratio
—
EPS
$-3.13
Beta
1.94
52W High
$122.20
52W Low
$58.71
50-Day MA
$87.07
200-Day MA
$98.66
Dividend Yield
—
Profit Margin
-93.30%
Forward P/E
—
PEG Ratio
—
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | $217.16M |
| Gross Profit (TTM) | $194.16M |
| EBITDA | $-196.17M |
| Operating Margin | -87.10% |
| Return on Equity | -101.20% |
| Return on Assets | -29.80% |
| Revenue/Share (TTM) | $3.28 |
| Book Value | $2.07 |
| Price-to-Book | 48.97 |
| Price-to-Sales (TTM) | 27.72 |
| EV/Revenue | 26.69 |
| EV/EBITDA | -12.65 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 83.80% |
| Shares Outstanding | $68.53M |
| Float | $55.69M |
| % Insiders | 0.77% |
| % Institutions | 109.95% |
Historical Volatility
HV 10-Day
59.86%
HV 20-Day
56.98%
HV 30-Day
48.07%
HV 60-Day
54.15%
HV Rank
52.0%
Volatility is currently expanding
Analyst Ratings
Consensus ($138.20 target)
4
Strong Buy11
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026